Back to top
more

Precision BioSciences (DTIL)

(Delayed Data from NSDQ)

$8.94 USD

8.94
42,871

-0.02 (-0.22%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $8.93 -0.01 (-0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Precision BioSciences (DTIL) Surpasses Q2 Earnings and Revenue Estimates

Precision BioSciences (DTIL) delivered earnings and revenue surprises of 194.74% and 202.63%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Precision BioSciences (DTIL) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Precision BioSciences (DTIL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Precision BioSciences (DTIL) Surges 6.6%: Is This an Indication of Further Gains?

Precision BioSciences (DTIL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Precision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue Estimates

Precision BioSciences (DTIL) delivered earnings and revenue surprises of 32.65% and 86.51%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Precision BioSciences (DTIL) Reports Q4 Loss, Tops Revenue Estimates

Precision BioSciences (DTIL) delivered earnings and revenue surprises of 12.00% and 136.97%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Will Precision BioSciences (DTIL) Report Negative Q4 Earnings? What You Should Know

Precision BioSciences (DTIL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Precision BioSciences' (DTIL) New Lymphoma Drug IND Gets FDA Nod

The FDA accepts Precision BioSciences' (DTIL) regulatory application to initiate a clinical study on its next-generation CD19 product candidate, PBCAR19B.

Lilly (LLY) Inks Deal With Merus to Discover Cancer Antibodies

Eli Lilly (LLY) signs a deal with Merus to develop novel T-cell re-directing bispecific antibodies. While Merus will lead early-stage development, Loxo Oncology will take care of further development and commercialization.

Lilly's (LLY) Coronavirus Treatment Gets Interim Nod in Canada

Lilly's (LLY) antibody drug bamlanivimab wins interim authorization from Health Canada to treat COVID-19. The company inks a genome editing research collaboration deal with Precision BioSciences.

Precision BioSciences (DTIL) Reports Q3 Loss, Tops Revenue Estimates

Precision BioSciences (DTIL) delivered earnings and revenue surprises of 26.47% and 73.25%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Precision BioSciences (DTIL) Q3 Earnings Expected to Decline

Precision BioSciences (DTIL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Precision BioSciences (DTIL) Reports Q2 Loss, Misses Revenue Estimates

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -5.00% and -80.81%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Precision BioSciences (DTIL) Q2 Earnings Expected to Decline

Precision BioSciences (DTIL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Precision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue Estimates

Precision BioSciences (DTIL) delivered earnings and revenue surprises of 1.89% and 34.71%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Precision BioSciences (DTIL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Precision BioSciences (DTIL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Precision BioSciences (DTIL) Report Negative Q1 Earnings? What You Should Know

Precision BioSciences (DTIL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Precision BioSciences, Inc. (DTIL) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Precision BioSciences, Inc. (DTIL).